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Introduction 
 
Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disorder, due to 
mutations of the CYP27A1 gene, leading to cholestanol accumulation because of the 
sterol-27-hydroxylase enzyme deficiency [1].  
Treatment with chenodeoxycholic acid (CDCA) normalizes cholestanol and improves 
neurophysiological findings.  
Several mutations of the CYP27A1 gene are described in different ethnic groups [1], 
without genotype–phenotype correlations. We describe two unrelated Sardinian families 
sharing the same CYP27A1 mutation. 
 
Family 1 
A 47 year-old-man, born from consanguineous parents from Olbia (northeastern Sardinia), 
showed cataracts at age 21, progressive walking difficulty since age 24 and severe bipolar 
disorder at 39. At age 43 tendon xantomas were identified. 
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Neurological examination revealed pareto-ataxic gait, hyperactive tendon reflexes, 
extensor plantar responses, asymmetrical accommodation reflex, mild cognitive 
impairment, defective attention and short-term memory deficit (Mini Mental Status 
Examination (MMSE): 21/30). Electromyography (EMG) revealed sensorimotor axonal 
polyneuropathy. 
Total cholesterol was 232 mg/dl.  
Electrocardiogram (ECG) showed signs of a previous myocardial infarction. 
Echocardiogram, brain and spinal cord Magnetic Resonance (MRI) were normal. 
The patient never received CDCA treatment.  
Cataracts and tendon xanthomas were also referred in his three brothers, who refused the 
genetic testing. 
 
Family 2 
Parents are first cousins from the Carbonia-Iglesias area (southwestern Sardinia). 
The proband, male, was evaluated at 45 years because of progressive walking difficulty. A 
diagnosis of spastic paraplegia was hypothesized but linkage analysis pointed to 
CYP27A1 locus. Neurological examination showed paretic gait, hyperactive tendon 
reflexes, extensor plantar responses, tendon xanthomas, buccal dyskinesia and moderate 
mental retardation. EMG demonstrated a mild sensorimotor polyneuropathy. Brain MRI 
showed multiple areas of white matter alterations. 
Serum cholestanol was 64.9 mg/l (nv<10) and cholesterol 254 mg/dl.  
Since age 53 he assumes CDCA 750 mg/die, with xantomatas reduction but no 
neurological improvement. 
 
The sister (46 years) reported two elbow neoformations removal (histology not available), 
progressive walking difficulties since age 34 and cataracts at 44 years. Neurological 
examination showed paretic gait, extensor plantar responses, long term attention deficit 
and a mild cognitive impairment (MMSE 20/30). Brain MRI was normal; spinal MRI 
showed a non-homogeneous cervical signal. ECG revealed an incomplete right bundle 
branch block. Serum cholestanol (28.3 mg/l) and total cholesterol (238 mg/dl) were 
increased. 
Since age 45 she assumes CDCA 750 mg/die, with symptomatology stabilization. 
 
 
Molecular analysis 
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Exons 1-9 and the promoter of the CYP27A1 gene were sequenced (protocol available 
upon request). Both families share the same homozygous mutation c.1435C>T, 
p.Arg479Cys, previously known as p.Arg446Cys [2], described as pathogenic in dbSNP 
(rs72551322) and reported only among European-American (MAF: 0.0001) in the Exome 
Variant Server (http://evs.gs.washington.edu/EVS/ [01,2014 accessed]). 
 
Two healthy relatives in family 2 (a 39 year-old niece and a 37 year-old nephew) carried a 
variant haplotype with c.888A>G, p.Gln296Gln (rs61733619) and c.1471G>T, p.Ala491Ser 
(rs72551323) variants, recorded in dbSNP as variants of unknown significance. The first 
has a MAF of 0,0233 among European-American. In silico splicing prediction didn’t show 
alterations (GeneSplicer: www.cbcb.umd.edu/software/GeneSplicer/gene_spl.shtml; 
MaxEntScan: http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html; 
NNSplice: www.fruitfly.org/seq_tools/splice.html). The p.Ala491Ser (MAF: 0,0019 among 
European-American) is predicted to be benign (SIFT: http://sift.jcvi.org/; PolyPhen-2: 
http://genetics.bwh.harvard.edu/pph2/; Mutation Taster: www.mutationtaster.org).  
The benign significance is also supported by the healthy status of the niece, who resulted 
to be a compound heterozygote with the p.Arg479Cys and the variant haplotype. Indeed, 
both she and her brother, who carries only the variant haplotype, have normal cholestanol 
(4.1 µg/l and 3.8 µg/l respectively).  
 
 
Discussion 
 
The phenotype of our patients is characteristic of CTX. 
The frequency of this disorder varies among populations and is higher in inbred ethnic 
groups [3]. In geographically isolated populations, such as Sardinia, the finding of founder 
mutations is expected [4].  
The p.Arg479Cys mutation was described either in homozygotes or compound 
heterozygotes [2, 5]. The affected Arginine is located next to Cysteine476 that binds the 
heme cofactor, thus it is predicted to alter enzyme activity. Transfection of mutant cDNAs 
into cells results in the synthesis of sterol 27-hydroxylase protein with greatly diminished 
enzyme activity [2].  
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